| Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial.Jpn J Ophthalmol | PMID 36897413PMC9999055 | 2023-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial.Eur J Cancer | PMID 36898233无 PMCID | 2023-May | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Defibrotide plus best standard of care compared with best standard of care alone for the prevention of sinusoidal obstruction syndrome (HARMONY): a randomised, multicentre, phase 3 trial.Lancet Haematol | PMID 37001534无 PMCID | 2023-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B): a multicentre, open-label, randomised, phase 3 trial.Lancet Haematol | PMID 37003278无 PMCID | 2023-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Predictors of response and remission in patients with treatment-resistant depression: A post hoc pooled analysis of two acute trials of esketamine nasal spray.Psychiatry Res | PMID 37019044无 PMCID | 2023-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| The efficacy and safety of nanoparticle albumin bound-paclitaxel-based regimen as second- or third-line treatment in patients with advanced esophageal squamous cell carcinoma.Thorac Cancer | PMID 37035870PMC10212655 | 2023-May | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 1-year results from the Japan subgroup of the phase 3 TENAYA trial.Jpn J Ophthalmol | PMID 37039948PMC10098238 | 2023-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study.Lancet Neurol | PMID 37059507无 PMCID | 2023-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study.Lancet Neurol | PMID 37059508无 PMCID | 2023-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Health-related quality of life of patients with resistant/intolerant chronic phase chronic myeloid leukemia treated with asciminib or bosutinib in the phase 3 ASCEMBL trial.Leukemia | PMID 37069326PMC10169655 | 2023-May | 0.95 | The report is from a Phase III randomized trial with a drug intervention in oncology, but it is a quality-of-life analysis (HRQOL) with patient-reported outcomes as the primary endpoint, not a time-to-event efficacy endpoint (e.g., OS, PFS). Therefore, it does not meet the inclusion criteria for a time-to-event efficacy endpoint. | 待处理 |
| Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study.Lancet Oncol | PMID 37080222无 PMCID | 2023-May | 1.00 | 命中用户提供的消化道肿瘤阳性参考集。 | 待处理 |
| Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial.Lancet Oncol | PMID 37080223PMC11075114 | 2023-May | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| The role of warm ischemia time on functional outcomes after robotic partial nephrectomy: a radionuclide renal scan study from the clock randomized trial.World J Urol | PMID 37085644PMC10188582 | 2023-May | 0.85 | The record describes a Phase 3 RCT with original results, but it evaluates a surgical procedure for functional outcomes, not a drug intervention with a time-to-event efficacy endpoint. | 待处理 |
| Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial.Lancet Oncol | PMID 37142374无 PMCID | 2023-May | 0.96 | 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 | 待处理 |
| Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials.Nat Med | PMID 37142763PMC10202800 | 2023-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Matching-Adjusted Indirect Comparisons of Diroximel Fumarate, Ponesimod, and Teriflunomide for Relapsing Multiple Sclerosis.CNS Drugs | PMID 37155132无 PMCID | 2023-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Triplet Strategies in Metastatic Clear Cell Renal Cell Carcinoma: A Worthy Option in the First-Line Setting?Am Soc Clin Oncol Educ Book | PMID 37207297PMC11584060 | 2023-May | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Combining histological grade, TILs, and the PD-1/PD-L1 pathway to identify immunogenic tumors and de-escalate radiotherapy in early breast cancer: a secondary analysis of a randomized clinical trial.J Immunother Cancer | PMID 37208129PMC10201214 | 2023-May | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF.Future Oncol | PMID 37309702无 PMCID | 2023-May | 0.95 | The record meets all eligibility criteria: it is an original formal result report of a human malignant-neoplasm Phase III randomized trial with a drug-containing intervention and a primary/key secondary time-to-event efficacy endpoint (PFS/OS as indicated by 'alive for longer without disease getting worse'). | 待处理 |
| Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial.Lancet | PMID 37003287无 PMCID | 2023-Apr-29 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| ESTIMation of the ABiLity of prophylactic central compartment neck dissection to modify outcomes in low-risk differentiated thyroid cancer: a prospective randomized trial.Trials | PMID 37118818PMC10142499 | 2023-Apr-28 | 0.45 | This is a protocol for a randomized Phase III trial in thyroid cancer, but it does not report results. The primary endpoint is 'excellent response' at 1 year, which is not a time-to-event outcome like OS, PFS, or DFS. While radioactive iodine is used, it is standard adjuvant therapy in both arms, and the study's intervention is surgical (prophylactic neck dissection vs. thyroidectomy alone). Therefore, it does not meet criteria for a drug intervention or time-to-event efficacy endpoint in a result report. | 待处理 |
| Spontaneous reperfusion enhances succinate concentration in peripheral blood from stemi patients but its levels does not correlate with myocardial infarct size or area at risk.Sci Rep | PMID 37106099PMC10140265 | 2023-Apr-27 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| The Efficacy of Lumateperone in Patients With Bipolar Depression With Mixed Features.J Clin Psychiatry | PMID 37103915无 PMCID | 2023-Apr-24 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Endovascular treatment versus no endovascular treatment after 6-24 h in patients with ischaemic stroke and collateral flow on CT angiography (MR CLEAN-LATE) in the Netherlands: a multicentre, open-label, blinded-endpoint, randomised, controlled, phase 3 trial.Lancet | PMID 37003289无 PMCID | 2023-Apr-22 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| The trajectory of clinical responses in patients with early rheumatoid arthritis who achieve sustained remission in response to abatacept: subanalysis of AVERT-2, a randomized phase IIIb study.Arthritis Res Ther | PMID 37087459PMC10122306 | 2023-Apr-22 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Radiotherapy or Surgery of the Axilla After a Positive Sentinel Node in Breast Cancer: 10-Year Results of the Randomized Controlled EORTC 10981-22023 AMAROS Trial.J Clin Oncol | PMID 36383926无 PMCID | 2023-Apr-20 | 0.95 | The study meets criteria for being an oncology, human, randomized, Phase III trial with original primary results and time-to-event efficacy endpoints (OS, DFS). However, it is excluded because both interventions are non-drug (surgical/radiotherapeutic), and the requirement is for a drug-containing intervention. | 待处理 |
| Cosmetic Results and Side Effects of Accelerated Partial-Breast Irradiation Versus Whole-Breast Irradiation for Low-Risk Invasive Carcinoma of the Breast: The Randomized Phase III IRMA Trial.J Clin Oncol | PMID 36623246无 PMCID | 2023-Apr-20 | 0.85 | The record is excluded because it does not meet the drug intervention requirement (radiation therapy only) and the provided abstract reports only on secondary safety/cosmetic endpoints, not the trial's primary time-to-event efficacy endpoint (ipsilateral breast tumor recurrence). | 待处理 |
| Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension.N Engl J Med | PMID 36877098无 PMCID | 2023-Apr-20 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults.N Engl J Med | PMID 37018468无 PMCID | 2023-Apr-20 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants.N Engl J Med | PMID 37018474无 PMCID | 2023-Apr-20 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma.J Clin Oncol | PMID 37068377无 PMCID | 2023-Apr-20 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Cerebral Oximetry Monitoring in Extremely Preterm Infants.N Engl J Med | PMID 37075142无 PMCID | 2023-Apr-20 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy.Brain | PMID 36350566PMC10115230 | 2023-Apr-19 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial.JAMA | PMID 37071094PMC10114040 | 2023-Apr-18 | 1.00 | 命中用户提供的消化道肿瘤阳性参考集。 | 待处理 |
| The success of anti-PD-1 with chemotherapy for esophageal squamous cell carcinoma.Cell Rep Med | PMID 37075702PMC10140387 | 2023-Apr-18 | 0.60 | The record describes a Phase III RCT with drug intervention in oncology, but the abstract does not explicitly specify a time-to-event efficacy endpoint (like OS, PFS, DFS, etc.) or Kaplan-Meier/HR data. Without this information, the time_to_event criterion cannot be established. | 待处理 |
| Efficacy and Safety of Ensitrelvir in Patients With Mild-to-Moderate Coronavirus Disease 2019: The Phase 2b Part of a Randomized, Placebo-Controlled, Phase 2/3 Study.Clin Infect Dis | PMID 36477182PMC10110269 | 2023-Apr-17 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2- Metastatic Breast Cancer.Clin Cancer Res | PMID 36749874PMC10102847 | 2023-Apr-14 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Quality-of-life outcomes and risk prediction for patients randomized to nivolumab plus ipilimumab vs nivolumab on LungMAP-S1400I.J Natl Cancer Inst | PMID 36625510PMC10086628 | 2023-Apr-11 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study.J Clin Oncol | PMID 36306479PMC10082298 | 2023-Apr-10 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Randomized Phase III Trial of Ganitumab With Interval-Compressed Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma: A Report From the Children's Oncology Group.J Clin Oncol | PMID 36669140PMC10082251 | 2023-Apr-10 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study.J Clin Oncol | PMID 36735893PMC10082300 | 2023-Apr-10 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Cancer.J Clin Oncol | PMID 36780610无 PMCID | 2023-Apr-10 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma.J Clin Oncol | PMID 37018919无 PMCID | 2023-Apr-10 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial.J Clin Oncol | PMID 37018920无 PMCID | 2023-Apr-10 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and axial involvement: results from two phase 3 studies.Arthritis Res Ther | PMID 37038159PMC10084601 | 2023-Apr-10 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Randomized phase III study of high-dose methotrexate and whole-brain radiotherapy with/without temozolomide for newly diagnosed primary CNS lymphoma: JCOG1114C.Neuro Oncol | PMID 36334050PMC10076938 | 2023-Apr-06 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib Trial.Oncologist | PMID 36576173PMC10078905 | 2023-Apr-06 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Safety, tolerability, and immunogenicity of V114 pneumococcal vaccine compared with PCV13 in a 2+1 regimen in healthy infants: A phase III study (PNEU-PED-EU-2).Vaccine | PMID 36841723无 PMCID | 2023-Apr-06 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Superior immunogenicity of high-dose quadrivalent inactivated influenza vaccine versus Standard-Dose vaccine in Japanese Adults ≥ 60 years of age: Results from a phase III, randomized clinical trial.Vaccine | PMID 36906404无 PMCID | 2023-Apr-06 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Sustained glucocorticoid tapering in the phase 3 trials of anifrolumab: a post hoc analysis of the TULIP-1 and TULIP-2 trials.Rheumatology (Oxford) | PMID 36018235PMC10070065 | 2023-Apr-03 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |